Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:

China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected

This article was originally published in PharmAsia News

  • News

Executive Summary

SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies
Table

View full table

Advertisement

Related Content

Scrip
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
Scrip
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
Pink Sheet
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
Pink Sheet
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets?
Scrip
RDPAC's Lobbying Efforts To Regulate China's Medical Representatives Likely To Pay Off This Year
Scrip
Shanghai Pharmaceutical Expands North; NDRC Price Cuts Impact M&A Targets
Scrip
Are Chinese Price Cut Fears Overstated? Volume Likely To Drive Pharma Industry Growth, Analysts Say
Scrip
MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how
Pink Sheet
MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how
Scrip
3SBIO Sees Slowdown In China Regulatory Approvals Following SFDA Restructure; Concerns Linger On Drug Pricing Examination
Advertisement
Tags:
UsernamePublicRestriction

Register

SC073750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By